MARKET

VYGR

VYGR

Voyager
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.05
+0.11
+1.23%
Closed 17:49 03/27 EDT
OPEN
8.57
PREV CLOSE
8.94
HIGH
9.37
LOW
8.51
VOLUME
440.82K
TURNOVER
--
52 WEEK HIGH
28.79
52 WEEK LOW
6.26
MARKET CAP
336.24M
P/E (TTM)
-7.1243
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of VYGR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VYGR stock price target is 24.93 with a high estimate of 43.00 and a low estimate of 14.00.

EPS

VYGR News

More
  • Edited Transcript of VYGR earnings conference call or presentation 3-Mar-20 9:30pm GMT
  • Thomson Reuters StreetEvents · 4d ago
  • Voyager Therapeutics Announces Cancellation of Presentation and Webcast at the Barclays Global Healthcare Conference
  • GlobeNewswire · 03/09 13:00
  • HC Wainwright & Co. Maintains Buy on Voyager Therapeutics, Lowers Price Target to $18
  • Benzinga · 03/04 16:19
  • Morgan Stanley Maintains Equal-Weight on Voyager Therapeutics, Lowers Price Target to $14
  • Benzinga · 03/04 13:26

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About VYGR

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's pipeline consists of programs for CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington's disease; Friedreich's ataxia; frontotemporal dementia/Alzheimer's disease, and severe chronic pain. The Company's clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson's disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.
More

Webull offers kinds of Voyager Therapeutics Inc stock information, including NASDAQ:VYGR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VYGR stock news, and many more online research tools to help you make informed decisions.